Market Trending News

This report provides an overview of the pipeline landscape for gastrointestinal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for gastroenteritis, enterocolitis, gastritis and peritonitis, and features dormant and discontinued products. Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications. There are 12 products in development for this indication. Some of Key Players are: Avexegen Therapeutics , BCWorld Pharm , Daewon Pharm , Daewoong Pharmaceutical , GlaxoSmithKline , Infant Bacterial Therapeutics, Kyowa Hakko Kirin , Leadiant Biosciences, Medicago , Nosopharm SAS, Ology Bioservices, Oncodesign, ProMetic Life Sciences , Recce , RedHill Biopharma , Regen

This report provides an overview of the pipeline landscape for renal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chronic kidney disease (chronic renal failure), kidney fibrosis, polycystic kidney disease and end-stage kidney disease (end-stage renal disease), and features dormant and discontinued products. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol. There are 58 products in development for this indication. Some of Key Players are:  AdAlta , Allena Pharmaceuticals , apceth Biopharma , Arch Biopartners , Astellas Pharma , AstraZeneca , Bayer , BiOrion Technologies , Boehringer Ing

Non-alcoholic steatohepatitis (NASH) is the severe form of non-alcoholic fatty liver disease (NAFLD), characterized by a buildup of fat in the liver. Globally, the NAFLD prevalence rate is estimated to be around 25% and a significant proportion of these people are progressing to NASH. The disease is more frequently progressive and may lead to cirrhosis with complications of hepatocellular carcinoma, liver failure and liver-related death or the requirement of liver transplantation, which is not always feasible. NASH is a major global healthcare problem as the number of NASH patients is increasing. NASH has been gradually rising in the Asia-Pacific region, owing to the growing prevalence of diabetes, obesity and metabolic syndromes, an aging population and increasingly Westernized lifestyles. Increasing risk factors will result in more people living with the condition and drive revenue growth. Patients with NAFLD and NASH are at increased risk of mortality as well as liver, cardiovascu

Atopic dermatitis (AD), also called atopic eczema, is a chronic, pruritic, inflammatory skin disease arising from a complex interrelationship of environmental, immunologic, genetic, and pharmacologic factors, with a characteristic phenotype and typically distributed skin lesions. It is one of the most common skin diseases, affecting approximately 20% of children and 1-3% of adults globally. AD is a genetically complex, familial transmitted disease with a strong maternal influence; a child possesses a two-fold risk of developing the disease if one of the parents is affected and a three-fold risk if both are affected. Many studies reported that increasing urbanization, westernization of lifestyle, obesity, lack of physical exercise, stress, food allergies, and pollution increase the risk of AD. The current marketed drug landscape in AD includes topical agents (corticosteroids and calcineurin inhibitors), systemic therapies (such as corticosteroids, cyclosporine, azathioprine, methotr

Mental Illness Drugs Market  Mental Illness is a psychological anomaly that is reflected in patient’s behavior through disability, distress, or any conduct that is not considered as normal mental development. The causes of mental lllness are very diverse and often unclear in most cases. This Report covers the manufacturers’ data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data. Besides, the report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers. Get a Sample Report:  www.reportsweb.com/inquiry&

The adoption of Artificial Intelligence (AI) and automation solutions has enabled organizations to tackle such market challenges while meeting consumer expectations. Moreover, these automation technologies focus more on enhancing the employee experience rather than replacing them. One of such technologies gaining rapid market traction is the RPA technology that handles repetitive and rule-based tasks without human intervention. Thus, RPA enables organizations to automate repetitive functions and focus more on core business tasks. In Small and Medium-scale Enterprises (SMEs) that face business limitations, in terms of financial and human resources allocation, the implementation of RPA is expected to provide growth avenues. As the deployment of RPA will assist an organization to keep its operations as lean as possible. Also, use of automation technologies has become a crucial factor to gain long-term profitable growth. These software bots exhibit the maximum efficiency and can work 2